TOTAL VOLUME:

$154.4b

24H VOL:

$290,393,159

24H TRANSACTIONS:

2,984,640,614

OPEN INTEREST:

$1,944,100,805

420,493

Markets across

40,511

events

MATCHED EVENTS:

4,612

PLATFORM COVERAGE:

5

Polymarket:

37%

VS.

Kalshi:

63%

BETA
Dashboards
Insights
Indices
API
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Elections
Crypto
Companies
Financials
Economics
Other
Entertainment
Science and Technology
Will CRISPR Therapeutics (CRSP) beat quarterly earnings?
polymarket

Will CRISPR Therapeutics (CRSP) beat quarterly earnings?

Volume:
$2,781

Will CRISPR Therapeutics (CRSP) beat quarterly earnings?

 - Polymarket

Will CRISPR Therapeutics (CRSP) beat quarterly earnings? - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Nov 2, 2026

Closed: Nov 2, 6:02 PM EST

polymarket

Polymarket

View
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

Will CRISPR Therapeutics (CRSP) beat quarterly earnings?

View
0%
64%
Yes 0¢No 100¢
—
N/A
$2,781
N/A
N/A
N/A
1d 18h 24m
No
Total markets: 1

Description

As of market creation, CRISPR Therapeutics is estimated to release earnings on November 4, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.06 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.06 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets reflect the selected street consensus estimate for GAAP EPS as of market creation. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Polymarket

As of market creation, CRISPR Therapeutics is estimated to release earnings on November 4, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.06 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.06 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets reflect the selected street consensus estimate for GAAP EPS as of market creation. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Frequently asked questions

On Polymarket, the dashboard for the CRISPR Therapeutics earnings market tracks the current odds, price history, and 24-hour trading volume. You can see how traders are pricing the probability of CRISPR Therapeutics beating quarterly earnings expectations. Currently, the volume is $2,506. The dashboard provides a visual representation of how sentiment shifts over time, allowing you to analyze market activity and potential trading opportunities related to this specific event. It’s a central hub for monitoring the market’s dynamics and understanding trader conviction.

Currently, prediction market participants are expressing a view on CRISPR Therapeutics' earnings that may differ from traditional analyst forecasts. While analysts provide estimates based on financial modeling and company reports, this market reflects the collective wisdom of traders who are incentivized to accurately predict the outcome. Discrepancies can arise due to differing interpretations of available information, access to non-public data, or simply varying levels of confidence in the company’s performance. Examining these differences can provide valuable insights into market sentiment and potential surprises.

This market resolves around Nov 4, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. Specifically, the resolution will be based on whether CRISPR Therapeutics reports quarterly earnings that exceed analyst expectations, as determined by a consensus estimate available at the time of the earnings release. The final result will be sourced from official company announcements and widely recognized financial news outlets. Traders will then be able to claim their winnings or adjust their strategies based on the verified outcome.

Several signals or events could significantly move this market before it resolves. Unexpected news regarding CRISPR Therapeutics’ clinical trial results, regulatory approvals, or competitive landscape could all influence trader sentiment. Additionally, broader market trends in the biotechnology sector or overall economic conditions could play a role. Any significant revisions to analyst earnings estimates, or even commentary from company executives, could also trigger price fluctuations. Monitoring these factors will be crucial for understanding the potential direction of this market.